

---

## Ngenic - Outcome in the rights issue

Redeye comments on the outcome of Ngenic's rights issue, which was subscribed to 88%, injecting Ngenic with approx. SEK30m before deductions for fees and offsetting of debt. We adjust our fair value range accordingly.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Ngenic - Outcome in the rights issue**